[Amodiaquine-induced hepatitis with leukopenia]

Area of Science:

• Pharmacology
• Hepatology
• Hematology

Background:

• Malaria remains a significant global health concern, necessitating effective chemoprophylaxis.
• Amodiaquine is a widely used antimalarial drug, particularly in endemic regions.
• Understanding drug-induced adverse events is crucial for patient safety.

Observation:

• Two patients developed hepatitis concurrent with granulocytopenia during amodiaquine prophylaxis.
• The clinical presentation suggested a potential adverse drug reaction.
• Symptoms were of short duration.

Findings:

• The adverse reaction was strongly suspected to be linked to amodiaquine.
• Re-administration of amodiaquine in one patient led to the recurrence of symptoms, confirming the drug's causal role.
• This case series highlights a specific pattern of amodiaquine-induced toxicity.

Implications:

• Clinicians should be vigilant for hepatitis and granulocytopenia in patients taking amodiaquine.
• This finding may inform prescribing guidelines and patient monitoring protocols for amodiaquine.
• Further research into the mechanisms of amodiaquine-induced liver and blood disorders is warranted.